BJT 574
Alternative Names: BJT-574Latest Information Update: 28 Feb 2022
At a glance
- Originator Novartis
- Developer Bluejay Therapeutics; Novartis
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis B surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatitis B
Most Recent Events
- 02 Feb 2022 Preclinical trials in Hepatitis B in USA (PO), prior to February 2022 (Bluejay Therapeutics pipeline, February 2022)
- 02 Feb 2022 Bluejay Therapeutics plans a phase Ia/b trial for Hepatitis B (PO), in 2024 (Bluejay Therapeutics pipeline, February 2022)
- 02 Feb 2022 Bluejay Therapeutics plans a phase II trial for Hepatitis B (PO), in 2025 (Bluejay Therapeutics pipeline, February 2022)